Trends in Hospitalization for Atrial Fibrillation: Epidemiology, Cost, and Implications for the Future

Progress in Cardiovascular Diseases

Volumn 58, Issue 2, 2015, Pages 105-116

  Sheikh, Azfar ^a   Patel, Nileshkumar J ^a   Nalluri, Nikhil ^a   Agnihotri, Kanishk ^b   Spagnola, Jonathan ^a   Patel, Aashay ^c   Asti, Deepak ^a   Kanotra, Ritesh ^a   Khan, Hafiz ^a   Savani, Chirag ^d   Arora, Shilpkumar ^e   Patel, Nilay ^b   Thakkar, Badal ^f   Patel, Neil ^g   Pau, Dhaval ^a   Badheka, Apurva O ^h   Deshmukh, Abhishek ⁱ   Kowalski, Marcin ^a   Viles Gonzalez, Juan ^j   Paydak, Hakan ^k  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f TULANE UNIVERSITY   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

more..

Author keywords

Atrial fibrillation; Cost analysis; Epidemiology; Future implications; Trends in hospitalization

Indexed keywords

AGE; ARTICLE; ATRIAL FIBRILLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MORTALITY; OUTPATIENT; PREVALENCE; PUBLIC HEALTH; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; THROMBOEMBOLISM; TREND STUDY; ADOLESCENT; ADULT; AGED; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FORECASTING; HOSPITAL COST; LENGTH OF STAY; MALE; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; FEMALE; FORECASTING; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942193578     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.07.002     Document Type: Article

References (73)

1. Colilla S., Crow A., Petkun W., Singer D.E., Simon T., Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013, 112:1142-1147.
2. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
3. Stewart S., Hart C.L., Hole D.J., McMurray J.J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002, 113:359-364.
4. Coyne K.S., Paramore C., Grandy S., Mercader M., Reynolds M., Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006, 9:348-356.
5. Moeremans K., Aliot E., de Chillou C., Annemans L., Le Pen C., de Jong P. Second line pharmacological management of paroxysmal and persistent atrial fibrillation in France: a cost analysis. Value Health 2000, 3:407-416.
6. Kim M.H., Johnston S.S., Chu B.C., Dalal M.R., Schulman K.L. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011, 4:313-320.
7. Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation 2014, 129:837-847.
8. Wolf P.A., Benjamin E.J., Belanger A.J., Kannel W.B., Levy D., D'Agostino R.B. Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am Heart J 1996, 131:790-795.
9. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up study. Am J Med 1995, 98:476-484.
10. Michelena H.I., Powell B.D., Brady P.A., Friedman P.A., Ezekowitz M.D. Gender in atrial fibrillation: ten years later. Gend Med 2010, 7:206-217.
11. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001, 285:2370-2375.
12. Alonso A., Agarwal S.K., Soliman E.Z., et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2009, 158:111-117.
13. Ruo B., Capra A.M., Jensvold N.G., Go A.S. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol 2004, 43:429-435.
14. Dewland T.A., Olgin J.E., Vittinghoff E., Marcus G.M. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 2013, 128:2470-2477.
15. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., Hart R.G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155:469-473.
16. Stefansdottir H., Aspelund T., Gudnason V., Arnar D.O. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011, 13:1110-1117.
17. Page R.L., Wilkinson W.E., Clair W.K., McCarthy E.A., Pritchett E.L. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994, 89:224-227.
18. Alonso A., Krijthe B.P., Aspelund T., et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013, e000102.
19. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2n-9n.
20. Tsang T.S., Barnes M.E., Bailey K.R., et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001, 76:467-475.
21. Jabre P., Jouven X., Adnet F., et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation 2011, 123:2094-2100.
22. Steger C., Pratter A., Martinek-Bregel M., et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004, 25:1734-1740.
23. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
24. Sanna T., Diener H.C., Passman R.S., et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014, 370:2478-2486.
25. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001, 86:516-521.
26. Almassi G.H., Schowalter T., Nicolosi A.C., et al. Atrial fibrillation after cardiac surgery: a major morbid event?. Ann Surg 1997, 226:501-511. [discussion 511-503].
27. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart study. JAMA 1994, 271:840-844.
28. Misialek J.R., Rose K.M., Everson-Rose S.A., et al. Socioeconomic status and the incidence of atrial fibrillation in whites and blacks: the Atherosclerosis Risk in Communities (ARIC) study. J Am Heart Assoc 2014, 3. [PMID: 25142059].
29. Mattioli A.V., Bonatti S., Zennaro M., Mattioli G. The relationship between personality, socio-economic factors, acute life stress and the development, spontaneous conversion and recurrences of acute lone atrial fibrillation. Europace 2005, 7:211-220.
30. Chamberlain A.M., Agarwal S.K., Folsom A.R., et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study heart rhythm. United States: 2011 Heart Rhythm Society 2011, 1160-1166. Published by Elsevier Inc.
31. Djousse L., Levy D., Benjamin E.J., et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham study. Am J Cardiol 2004, 93:710-713.
32. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292:2471-2477.
33. Fuso L., Incalzi R.A., Pistelli R., et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995, 98:272-277.
34. Cadby G., McArdle N., Briffa T., et al. Severity of obstructive sleep apnea is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest 2015, [PMID: 25927872].
35. Nichols G.A., Reinier K., Chugh S.S. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009, 32:1851-1856.
36. Auer J., Scheibner P., Mische T., Langsteger W., Eber O., Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001, 142:838-842.
37. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004, 164:1675-1678.
38. Kerr C., Boone J., Connolly S., et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 1996, 17(Suppl. C):48-51.
39. Rodondi N., Bauer D.C., Cappola A.R., et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J Am Coll Cardiol 2008, 52:1152-1159.
40. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol 2011, 4:26-32.
41. Lindhardsen J., Ahlehoff O., Gislason G.H., et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012, 344:e1257.
42. Emilsson L., Smith J.G., West J., Melander O., Ludvigsson J.F. Increased risk of atrial fibrillation in patients with coeliac disease: a nationwide cohort study. Eur Heart J 2011, 32:2430-2437.
43. Patel N.J., Deshmukh A., Pant S., et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 2014, 129:2371-2379.
44. Naderi S., Wang Y., Miller A.L., et al. The impact of age on the epidemiology of atrial fibrillation hospitalizations. Am J Med 2014, 127:158.e151-158.e157.
45. Mujib M., Zhang Y., Feller M.A., Ahmed A. Evidence of a "heart failure belt" in the southeastern United States. Am J Cardiol 2011, 107:935-937.
46. Gillum R.F., Ingram D.D. Relation between residence in the southeast region of the United States and stroke incidence. The NHANES I Epidemiologic Followup Study. Am J Epidemiol 1996, 144:665-673.
47. Stewart S., Murphy N.F., Walker A., McGuire A., McMurray J.J. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004, 90:286-292.
48. Clemens A., Peng S., Brand S., et al. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. Am J Cardiol 2014, 114:849-855.
49. Chan P.S., Vijan S., Morady F., Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006, 47:2513-2520.
50. Badheka A.O., Chothani A., Mehta K., et al. Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume. Circ Arrhythm Electrophysiol 2015, 8:42-48.
51. Catherwood E., Fitzpatrick W.D., Greenberg M.L., et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999, 130:625-636.
52. Wolf P.A., Mitchell J.B., Baker C.S., Kannel W.B., D'Agostino R.B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998, 158:229-234.
53. Reynolds M.R., Essebag V., Zimetbaum P., Cohen D.J. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007, 18:628-633.
54. Reardon G., Nelson W.W., Patel A.A., Philpot T., Neidecker M. Prevalence of atrial fibrillation in US nursing homes: results from the National Nursing Home Survey, 1985-2004. J Am Med Dir Assoc 2012, 13:529-534.
55. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012, 33:1500-1510.
56. Lee S., Anglade M.W., Pham D., Pisacane R., Kluger J., Coleman C.I. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012, 110:845-851.
57. Shah S.V., Gage B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011, 123:2562-2570.
58. Adcock A.K., Lee-Iannotti J.K., Aguilar M.I., et al. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Neurologist 2012, 18:102-107.
59. Kamel H., Johnston S.C., Easton J.D., Kim A.S. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012, 43:881-883.
60. Harrington A.R., Armstrong E.P., Nolan P.E., Malone D.C. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013, 44:1676-1681.
61. Stoddard M.F., Dawkins P.R., Prince C.R., Ammash N.M. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995, 25:452-459.
62. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996, 61:755-759.
63. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374:534-542.
64. Urena M., Rodes-Cabau J., Freixa X., et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013, 62:96-102.
65. Bartus K., Han F.T., Bednarek J., et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013, 62:108-118.
66. Ezekowitz M.D., Kent A.P. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. Circulation 2014, 130:1505-1514.
67. Haissaguerre M., Hocini M., Shah A.J., et al. Noninvasive panoramic mapping of human atrial fibrillation mechanisms: a feasibility report. J Cardiovasc Electrophysiol 2013, 24:711-717.
68. Hakalahti A., Biancari F., Nielsen J.C., Raatikainen M.J. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace 2015, 17:370-378.
69. Calkins H., Reynolds M.R., Spector P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009, 2:349-361.
70. Deshmukh A., Patel N.J., Pant S., et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 2013, 128:2104-2112.
71. Reynolds M.R., Zimetbaum P., Josephson M.E., Ellis E., Danilov T., Cohen D.J. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2009, 2:362-369.
72. Mandell J., Amico F., Parekh S., Snow J., Germano J., Cohen T.J. Early experience with the cryoablation balloon procedure for the treatment of atrial fibrillation by an experienced radiofrequency catheter ablation center. J Invasive Cardiol 2013, 25:288-292.
73. Cheng X., Hu Q., Zhou C., et al. The long-term efficacy of cryoballoon vs irrigated radiofrequency ablation for the treatment of atrial fibrillation: a meta-analysis. Int J Cardiol 2015, 181:297-302.